Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine H Han

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cancer|September 27, 2017
Diagnosis and management of primary central nervous system lymphomaCatherine H Han, Tracy T Batchelor
Frontiers in Oncology|October 11, 2017
Genetic Characterization of Brain Metastases in the Era of Targeted TherapyCatherine H Han, Priscilla K Brastianos
Continuum (Minneapolis, Minn.)|December 5, 2017
Primary Central Nervous System LymphomaCatherine H Han, Tracy T Batchelor
Chinese Clinical Oncology|July 15, 2017
Isocitrate dehydrogenase mutation as a therapeutic target in gliomasCatherine H Han, Tracy T Batchelor
Therapeutic Advances in Neurological Disorders|October 12, 2018
Primary central nervous system lymphomaSarah Löw, Catherine H Han, Tracy T Batchelor
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|November 11, 2019
Muscle ultrasound in the assessment of oxaliplatin-induced neurotoxicityLuciana Pelosi, Catherine H Han, Mark J McKeage
BMC Cancer|October 26, 2013
Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patientsCatherine H Han, Prashannata Khwaounjoo, Dean H Kilfoyle, et al.
Scientific Reports|June 24, 2017
Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradationCatherine H Han, Prashannata Khwaounjoo, Andrew G Hill, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 20, 2016
Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeuticsCatherine H Han, Dean H Kilfoyle, Andrew G Hill, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Contemporary Patterns of Care for Low-Grade Glioma in Australia and New ZealandMeghana Maddula, Nicholas McNamee, Hui K Gan, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancer|September 27, 2017
Diagnosis and management of primary central nervous system lymphomaCatherine H Han, Tracy T Batchelor
Frontiers in Oncology|October 11, 2017
Genetic Characterization of Brain Metastases in the Era of Targeted TherapyCatherine H Han, Priscilla K Brastianos
Continuum (Minneapolis, Minn.)|December 5, 2017
Primary Central Nervous System LymphomaCatherine H Han, Tracy T Batchelor
Chinese Clinical Oncology|July 15, 2017
Isocitrate dehydrogenase mutation as a therapeutic target in gliomasCatherine H Han, Tracy T Batchelor
Therapeutic Advances in Neurological Disorders|October 12, 2018
Primary central nervous system lymphomaSarah Löw, Catherine H Han, Tracy T Batchelor
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|November 11, 2019
Muscle ultrasound in the assessment of oxaliplatin-induced neurotoxicityLuciana Pelosi, Catherine H Han, Mark J McKeage
BMC Cancer|October 26, 2013
Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patientsCatherine H Han, Prashannata Khwaounjoo, Dean H Kilfoyle, et al.
Scientific Reports|June 24, 2017
Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradationCatherine H Han, Prashannata Khwaounjoo, Andrew G Hill, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 20, 2016
Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeuticsCatherine H Han, Dean H Kilfoyle, Andrew G Hill, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Contemporary Patterns of Care for Low-Grade Glioma in Australia and New ZealandMeghana Maddula, Nicholas McNamee, Hui K Gan, et al.
Pageof 2